title: Stacking up CRISPR against RNAi for therapeutic gene inhibition.
abstract: Both RNA interference (RNAi) and clustered regularly-interspaced short palindromic repeats (CRISPR) technologies allow for the sequence-specific inhibition of gene function and therefore have the potential to be used as therapeutic modalities. By judging the current public and scientific journal interest, it would seem that CRISPR, by enabling clean, durable knockouts, will dominate therapeutic gene inhibition, also at the expense of RNAi. This review aims to look behind prevailing sentiments and to more clearly define the likely scope of the therapeutic applications of the more recently developed CRISPR technology and its relative strengths and weaknesses with regards to RNAi. It is found that largely because of their broadly overlapping delivery constraints, while CRISPR presents formidable competition for DNA-directed RNAi strategies, its impact on RNAi therapeutics triggered by synthetic oligonucleotides will likely be more moderate. Instead, RNAi and genome editing, and in particular CRISPR, are poised to jointly promote a further shift toward sequence-targeted precision medicines.
authors.affiliation: Rastatt, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Haussecker
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D064113:CRISPR-Cas Systems; D064987:Cell- and Tissue-Based Therapy; D000072669:Gene Editing; D055786:Gene Knockout Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008099:Liver / Q000378:metabolism; D034622:RNA Interference; D016372:RNA, Antisense / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use
chemical_list: D016372:RNA, Antisense
keywords: RNA interference; clustered regularly-interspaced short palindromic repeats; gene therapy; nucleic acid therapeutics; oligonucleotide therapeutics